US7118757B1
(en)
|
1988-12-19 |
2006-10-10 |
Wyeth Holdings Corporation |
Meningococcal class 1 outer-membrane protein vaccine
|
EP0467714A1
(en)
*
|
1990-07-19 |
1992-01-22 |
Merck & Co. Inc. |
The class II protein of the outer membrane of neisseria meningitidis
|
CA2071088A1
(en)
*
|
1991-06-19 |
1992-12-20 |
Emilio A. Emini |
Conjugates of the class ii protein of the outer membrane of neisseria meningitidis and of hiv-1 related peptides, and vaccines containing same
|
EP0909323B1
(en)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Helicobacter pylori bacterioferritin
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
NZ533428A
(en)
|
2001-12-12 |
2008-03-28 |
Chiron Srl |
Immunisation against chlamydia trachomatis
|
CA2476626A1
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
DE60328481D1
(de)
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
SI2351579T1
(sl)
|
2002-10-11 |
2017-05-31 |
Glaxosmithkline Biologicals Sa |
Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
CN101926988B
(zh)
|
2003-01-30 |
2014-06-04 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
US9107831B2
(en)
|
2003-06-02 |
2015-08-18 |
Novartis Vaccines And Diagonstics, Inc. |
Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
ATE506963T1
(de)
|
2003-10-02 |
2011-05-15 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen meningitis
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
HUE030881T2
(en)
|
2005-02-18 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
EP2329843A3
(en)
|
2005-04-18 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Expressing Hepatitis B Virus surface antigen for vaccine preparation
|
HUE031380T2
(en)
|
2005-06-27 |
2017-07-28 |
Glaxosmithkline Biologicals Sa |
A method for producing vaccines
|
AU2006286228A1
(en)
|
2005-09-01 |
2007-03-08 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Multiple vaccination including serogroup C meningococcus
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
EP2360175B1
(en)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and Sapovirus virus-like particles (VLPs)
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2808919C
(en)
|
2005-12-22 |
2016-04-19 |
Glaxosmithkline Biologicals S.A. |
Streptococcus pneumoniae capsular saccharide vaccine
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
ES2670231T3
(es)
|
2006-03-22 |
2018-05-29 |
Glaxosmithkline Biologicals S.A. |
Regímenes para inmunización con conjugados meningocócicos
|
ES2376492T3
(es)
|
2006-03-23 |
2012-03-14 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores.
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
PT2066344E
(pt)
|
2006-09-07 |
2011-07-05 |
Glaxosmithkline Biolog Sa |
Vacina de combinação de poliovírus inactivado
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
UY31064A1
(es)
|
2007-05-02 |
2009-01-05 |
Glaxosmithkline Biolog Sa |
Vacuna
|
DK2167121T3
(da)
|
2007-06-26 |
2015-11-23 |
Glaxosmithkline Biolog Sa |
Vaccine omfattende Streptococcus pneumonia-kapselpolysaccharidkonjugater
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0816689B1
(pt)
|
2007-09-12 |
2021-08-24 |
Novartis Ag |
Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
|
SI2200642T1
(sl)
|
2007-10-19 |
2012-06-29 |
Novartis Ag |
Formulacije meningokoknega cepiva
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ601543A
(en)
|
2007-12-21 |
2013-03-28 |
Novartis Ag |
Mutant forms of streptolysin o
|
EP2886551A3
(en)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningococcal fhbp polypeptides
|
AU2009309416B2
(en)
|
2008-10-27 |
2015-05-28 |
Glaxosmithkline Biologicals S.A. |
Purification method
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
AU2009329193A1
(en)
|
2008-12-17 |
2011-07-14 |
Novartis Ag |
Meningococcal vaccines including hemoglobin receptor
|
CA2748788C
(en)
|
2009-01-05 |
2021-02-09 |
Epitogenesis Inc. |
The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
EP2470204B1
(en)
|
2009-08-27 |
2015-12-16 |
GlaxoSmithKline Biologicals SA |
Hybrid polypeptides including meningococcal fhbp sequences
|
KR101660578B1
(ko)
|
2009-09-03 |
2016-09-27 |
화이자 백신스 엘엘씨 |
Pcsk9 백신
|
KR20120081587A
(ko)
|
2009-09-10 |
2012-07-19 |
노파르티스 아게 |
기도 질병에 대한 조합 백신
|
CA2779798C
(en)
|
2009-09-30 |
2019-03-19 |
Novartis Ag |
Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
WO2011039631A2
(en)
|
2009-09-30 |
2011-04-07 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptídeos de modificação meningocócica fhbp"
|
AU2010310919B2
(en)
|
2009-10-30 |
2015-05-07 |
Glaxosmithkline Biologicals S.A. |
Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
EP2667852B1
(en)
|
2011-01-27 |
2016-11-09 |
GlaxoSmithKline Biologicals SA |
Adjuvant nanoemulsions with crystallisation inhibitors
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
US10357568B2
(en)
|
2011-03-24 |
2019-07-23 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with phospholipids
|
EP2511295A1
(en)
|
2011-04-15 |
2012-10-17 |
Institut National De La Sante Et De La Recherche Medicale |
Compositions for preventing and/or treating an infection by an HIV-1 virus
|
AU2012272652B2
(en)
|
2011-06-24 |
2017-06-01 |
Epitogenesis Inc. |
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
JP6170932B2
(ja)
|
2011-11-07 |
2017-07-26 |
ノバルティス アーゲー |
spr0096抗原およびspr2021抗原を含むキャリア分子
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
EP2592137A1
(en)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
ES2704069T3
(es)
|
2011-12-08 |
2019-03-14 |
Glaxosmithkline Biologicals Sa |
Vacuna basada en toxinas de Clostridium difficile
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
MX2014010011A
(es)
|
2012-02-24 |
2014-09-08 |
Novartis Ag |
Proteinas y composiciones de pilus.
|
US20150132339A1
(en)
|
2012-03-07 |
2015-05-14 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
BR112014026812A8
(pt)
|
2012-04-26 |
2022-10-04 |
Novartis Ag |
Antígenos e combinações de antígenos
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
Глэксосмитиклайн Байолоджикалз Са |
Иммуногенные композиции
|
EP3620172A1
(en)
|
2012-10-12 |
2020-03-11 |
GlaxoSmithKline Biologicals SA |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
AU2013351182C1
(en)
|
2012-11-30 |
2018-11-08 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
CA2899787A1
(en)
|
2013-02-01 |
2014-08-07 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor agonists
|
MX369534B
(es)
|
2013-09-08 |
2019-11-11 |
Pfizer |
Composiciones de neisseria meningitidis y sus metodos.
|
MX371453B
(es)
|
2014-01-21 |
2020-01-29 |
Pfizer |
Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CN105934251A
(zh)
|
2014-01-21 |
2016-09-07 |
辉瑞大药厂 |
肺炎链球菌荚膜多糖及其缀合物
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
ES2930318T3
(es)
|
2014-02-14 |
2022-12-09 |
Pfizer |
Conjugados glucoproteicos inmunogénicos
|
HUE052293T2
(hu)
|
2014-02-28 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Módosított fHbp meningococcus-polipeptidek
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
FI3244917T3
(fi)
|
2015-01-15 |
2023-05-25 |
Pfizer |
Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
|
WO2016184963A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
WO2016184962A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
EP3109255A1
(en)
|
2015-06-26 |
2016-12-28 |
Institut National De La Recherche Agronomique |
Immunogenic composition
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
RU2021109510A
(ru)
|
2015-12-04 |
2021-04-16 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Вакцинация с использованием альфа 3 домена mica/b для лечения рака
|
US11612664B2
(en)
|
2016-04-05 |
2023-03-28 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
US20190282684A1
(en)
|
2016-09-02 |
2019-09-19 |
Glaxosmithkline Biologicals, S.A. |
Vaccines for neisseria gonorrhoeae
|
US11478538B2
(en)
|
2016-10-07 |
2022-10-25 |
Enterome S.A. |
Immunogenic compounds for cancer therapy
|
AU2017339577B2
(en)
|
2016-10-07 |
2021-12-02 |
Enterome S.A. |
Immunogenic compounds for cancer therapy
|
EP3551668A1
(en)
|
2016-12-06 |
2019-10-16 |
GlaxoSmithKline Biologicals S.A. |
Purification process for capsular polysaccharide
|
DK3570879T3
(da)
|
2017-01-20 |
2022-04-11 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
JP7010961B2
(ja)
|
2017-01-31 |
2022-02-10 |
ファイザー・インク |
髄膜炎菌組成物およびその方法
|
WO2019197563A2
(en)
|
2018-04-11 |
2019-10-17 |
Enterome S.A. |
Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
|
BR112020020780A2
(pt)
|
2018-04-11 |
2021-03-02 |
Enterome S.A. |
peptídeos antigênicos para prevenção e tratamento do câncer
|
WO2020016322A1
(en)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
EP3607967A1
(en)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modified meningococcal fhbp polypeptides
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
WO2020165711A1
(en)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
Neisseria meningitidiscompositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
JP2022528158A
(ja)
|
2019-04-10 |
2022-06-08 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
|
BR112021022429A2
(pt)
|
2019-05-10 |
2022-03-22 |
Glaxosmithkline Biologicals Sa |
Produção de conjugados
|
EP4003410A1
(en)
|
2019-07-31 |
2022-06-01 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
CN115605222A
(zh)
|
2019-09-27 |
2023-01-13 |
辉瑞公司(Us) |
脑膜炎奈瑟氏菌组合物及其方法
|
MX2022004598A
(es)
|
2019-10-16 |
2022-09-23 |
Enterome S A |
Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
|
IL292494A
(en)
|
2019-11-01 |
2022-06-01 |
Pfizer |
Preparations of Escherichia coli and their methods
|
DK4021487T3
(da)
|
2019-11-15 |
2024-02-12 |
Enterome S A |
Antigene peptider til forebyggelse og behandling af b-celle malignitet
|
EP4061412A1
(en)
|
2019-11-22 |
2022-09-28 |
GlaxoSmithKline Biologicals S.A. |
Dosage and administration of a bacterial saccharide glycoconjugate vaccine
|
AU2021224078B2
(en)
|
2020-02-21 |
2024-01-18 |
Pfizer Inc. |
Purification of saccharides
|
EP4107170A2
(en)
|
2020-02-23 |
2022-12-28 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20230250142A1
(en)
|
2020-06-12 |
2023-08-10 |
Glaxosmithkline Biologicals Sa |
Dock tag system
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
EP4232593A1
(en)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
EP4070814A1
(en)
|
2021-04-07 |
2022-10-12 |
Lama France |
Sars-cov-2 polypeptides and uses thereof
|
JP2024517780A
(ja)
|
2021-05-03 |
2024-04-23 |
ファイザー・インク |
細菌およびベータコロナウイルス感染症に対するワクチン接種
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
PE20240090A1
(es)
|
2021-05-28 |
2024-01-16 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023187127A1
(en)
|
2022-03-31 |
2023-10-05 |
Enterome S.A. |
Antigenic peptides for prevention and treatment of cancer
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|